355 related articles for article (PubMed ID: 18756899)
21. A fuzzy-classifier using a marker panel for the detection of lung cancers in asbestosis patients.
Schneider J; Bitterlich N; Kotschy-Lang N; Raab W; Woitowitz HJ
Anticancer Res; 2007; 27(4A):1869-77. PubMed ID: 17649786
[TBL] [Abstract][Full Text] [Related]
22. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
[TBL] [Abstract][Full Text] [Related]
23. Determining the cut-off value of pro-gastrin releasing peptide (ProGRP) in lung cancer according to population characteristics.
Bubanović G; Pavićević R; Franjević A
Coll Antropol; 2008 Dec; 32(4):1155-64. PubMed ID: 19149223
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of CYFRA 21-1 in non-small cell lung cancer.
Hirashima T; Takada M; Komiya T; Nitta T; Masashi K; Masuda N; Matui K; Kikui M; Yasumitsu T; Kawase I
Anticancer Res; 1998; 18(6B):4713-6. PubMed ID: 9891546
[TBL] [Abstract][Full Text] [Related]
25. Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer.
Holdenrieder S; Von Pawel J; Duell T; Feldmann K; Raith H; Schollen A; Nagel D; Stieber P
Anticancer Res; 2010 May; 30(5):1855-62. PubMed ID: 20592392
[TBL] [Abstract][Full Text] [Related]
26. Decision guarantee in tumour marker analysis: a cut-off independent assessment.
Bitterlich N; Schneider J
Anticancer Res; 2007; 27(4A):1933-9. PubMed ID: 17649799
[TBL] [Abstract][Full Text] [Related]
27. CYFRA 21-1 in the early diagnosis of recurrent disease in non small cell lung carcinomas (NSCLC).
Stieber P; Zimmermann A; Reinmiedl J; Müller C; Hoffmann H; Dienemann H
Anticancer Res; 1999; 19(4A):2665-8. PubMed ID: 10470216
[TBL] [Abstract][Full Text] [Related]
28. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
29. Cut-off-independent tumour marker evaluation using ROC approximation.
Bitterlich N; Schneider J
Anticancer Res; 2007; 27(6C):4305-10. PubMed ID: 18214036
[TBL] [Abstract][Full Text] [Related]
30. Cut-off value determination of CYFRA 21-1 for squamous cell carcinomas of the head and neck (SCCHN).
Niemann AM; Goeroegh T; Gottschlich S; Lippert BM; Werner JA
Anticancer Res; 1997; 17(4B):2859-60. PubMed ID: 9329547
[TBL] [Abstract][Full Text] [Related]
31. [Clinical usefulness of serum assay of EIA-CYFRA 21-1 in lung cancer].
Satoh H; Yagyu H; Sumi M; Ishikawa H; Hamada M; Suyama T; Naitoh T; Inoue M; Saitoh T; Uchida Y
Gan To Kagaku Ryoho; 1994 May; 21(6):795-9. PubMed ID: 7514388
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer.
Nisman B; Amir G; Lafair J; Heching N; Lyass O; Peretz T; Barak V
Anticancer Res; 1999; 19(4C):3549-52. PubMed ID: 10629651
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of CYFRA 21-1 in malignant and benign pleural effusions.
Toumbis M; Rasidakis A; Passalidou E; Kalomenidis J; Alchanatis M; Orphanidou D; Jordanoglou J
Anticancer Res; 1996; 16(4A):2101-4. PubMed ID: 8712750
[TBL] [Abstract][Full Text] [Related]
35. Centre-independent detection of non-small cell lung cancer (NSCLC) by means of classification with receiver operating characteristic (ROC)-based data transformation.
Bitterlich N; Muley T; Schneider J
Anticancer Res; 2010 May; 30(5):1661-5. PubMed ID: 20592358
[TBL] [Abstract][Full Text] [Related]
36. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M
Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443
[TBL] [Abstract][Full Text] [Related]
37. Serum tumor marker CYFRA 21-1 in the diagnostics of squamous cell lung cancer--comparison with CEA.
Berzinec P; Zuffová H; Letkovicová M; Arpásová M
Neoplasma; 1996; 43(3):159-61. PubMed ID: 8841502
[TBL] [Abstract][Full Text] [Related]
38. Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLC.
Muley T; Fetz TH; Dienemann H; Hoffmann H; Herth FJ; Meister M; Ebert W
Lung Cancer; 2008 Jun; 60(3):408-15. PubMed ID: 18083270
[TBL] [Abstract][Full Text] [Related]
39. CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients.
Muley T; Dienemann H; Ebert W
Anticancer Res; 2004; 24(3b):1953-6. PubMed ID: 15274383
[TBL] [Abstract][Full Text] [Related]
40. Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma.
Zhong LP; Zhu HG; Zhang CP; Chen WT; Zhang ZY
Int J Oral Maxillofac Surg; 2007 Mar; 36(3):230-4. PubMed ID: 16965897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]